Envista (NYSE:NVST) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Envista (NYSE:NVST) announced its quarterly earnings data on Wednesday. The company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.36 by $0.04, FiscalAI reports. Envista had a return on equity of 7.88% and a net margin of 3.33%. The company had revenue of $691.50 million during the quarter, compared to analyst estimates of $688.74 million. During the same quarter last year, the firm posted $0.32 EPS. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis.

Here are the key takeaways from Envista’s conference call:

• Envista reported 2.7% core sales growth, with adjusted EBITDA up 9% and adjusted EPS up 25%; gross and EBITDA margins expanded 20 and 80 basis points, respectively. Free cash flow conversion was 97%, and net leverage remained low at 0.6x.
• The company raised its 2026 outlook, now expecting 3.75%–4.25% core sales growth, 12.5%–14% adjusted EBITDA growth, and adjusted EPS of $1.54–$1.58. Management said the fourth-quarter outlook implies slightly negative core growth, partly reflecting four fewer selling days and continued macro uncertainty.
• China sales fell at a low-double-digit rate as orthodontics customers destocked ahead of VBP; management expects the process to bring substantial price reductions, including about 50% for orthodontics and 10%–15% for implants. It expects VBP to support volume and share gains, but acknowledged margin pressure in China.
• Spark grew at a high-single-digit rate, diagnostics and implants each grew mid-single digits, and Envista said it continued to gain share in diagnostics. Management highlighted a strong new-product pipeline and said broader commercialization of recent launches will be a key growth priority for 2027.

Envista Price Performance

Shares of NVST traded up $2.44 during midday trading on Wednesday, hitting $27.21. 6,113,924 shares of the company traded hands, compared to its average volume of 3,135,394. The stock has a 50-day moving average of $24.49 and a 200-day moving average of $25.74. Envista has a one year low of $18.77 and a one year high of $30.42. The firm has a market cap of $4.37 billion, a P/E ratio of 46.91, a PEG ratio of 1.26 and a beta of 0.94. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.43 and a quick ratio of 2.07.

Insider Activity at Envista

In other news, SVP Mischa Reis sold 8,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $27.50, for a total value of $220,000.00. Following the completion of the transaction, the senior vice president directly owned 27,321 shares in the company, valued at approximately $751,327.50. This trade represents a 22.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.99% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on NVST. Robert W. Baird lowered shares of Envista from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $34.00 to $26.00 in a research report on Thursday, October 15th. Deutsche Bank Aktiengesellschaft set a $32.00 price target on shares of Envista in a research report on Thursday, September 3rd. Leerink Partners dropped their price target on shares of Envista from $35.00 to $32.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 14th. Morgan Stanley set a $23.00 price objective on shares of Envista in a report on Thursday, August 6th. Finally, Piper Sandler cut their price objective on shares of Envista from $28.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, October 9th. Six analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $28.86.

Envista Company Profile

Envista Holdings Corporation (NYSE: NVST) is a global dental products and technologies company headquartered in Brea, California. The company develops, manufactures and markets products used by dentists, dental specialists, dental laboratories and other oral health professionals.

Envista’s portfolio includes dental implants, orthodontic systems, digital imaging and workflow solutions, dental consumables, treatment equipment and related technologies. Its brands include Nobel Biocare, Ormco, DEXIS and Kerr, which provide products and services spanning implant dentistry, orthodontics, diagnostic imaging, restorative care and general dental practice management.

Envista was established as an independent public company in 2019 following its separation from Danaher Corporation.